SML3799

Nilotinib

≥98% (HPLC)

• 同義詞: 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide, 4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide, AMN 107, AMN107
• 經驗公式（希爾表示法）: C₂₈H₂₂F₃N₇O
• CAS號碼: 641571-10-0
• 分子量：: 529.52
• MDL號碼: MFCD09833716
• 分類程式碼代碼: 12352200
• NACRES: NA.21

屬性

• 品質等級: 100
• 化驗: ≥98% (HPLC)
• 形狀: powder
• 顏色: white to beige
• 溶解度: DMSO: 2 mg/mL, clear (Warmed)
• 儲存溫度: 2-8°C
• SMILES 字串: FC(F)(F)c1cc(cc(c1)NC(=O)c3cc(c(cc3)C)Nc4nc(ccn4)c5cnccc5)[n]2cnc(c2)C
• InChI: 1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)
• InChI 密鑰: HHZIURLSWUIHRB-UHFFFAOYSA-N

描述

生化／生理作用

Nilotinib (AMN107) is an orally available, selective and potent ATP-competitive wild-type and mutant Bcr-Abl kinase inhibitor that is 10-30-fold more potent than imatinib. Nilotinib is used to treat Philadelphia chromosome (Ph+)-positive chronic myelogenous leukemia (CML). Nilotinib reduces midbrain Bcr-Abl autophosphorylation, amyloid-β levels, and neuronal loss, as well as improves autophagosome clearance and reverses cognitive deficits in the Tg2576 transgenic mouse model of Alzheimer’s disease.

Orally available, selective and potent ATP-competitive wild-type and mutant Bcr-Abl kinase inhibitor

安全資訊

• 象形圖: GHS08
• 訊號詞: Danger
• 危險聲明: H372,H413
• 防範說明: P260 - P264 - P270 - P273 - P314 - P501
• 危險分類: Aquatic Chronic 4 - STOT RE 1
• 標靶器官: Liver,Kidney,gallbladder
• 儲存類別代碼: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• 水污染物質分類（WGK）: WGK 2
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable